Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01822015

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving sirolimus together with idarubicin and cytarabine may kill more cancer cells.

Status: 
Recruiting
Study Date: 
Fri, 03/01/2013 to Thu, 03/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Sirolimus Given PO Other Names: rapamycin Rapamune Drug: Idarubicin Given IV Other Names: 4-demethoxydaunorubicin Zavedos Idamycin Drug: Cytarabine Given IV Other Names: cytosine arabinoside Cytosar-U Depocyt Ara-C Arabinofuranosyl Cytidine